Marvel Biosciences Corp (MRVL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Marvel Biosciences Corp (MRVL) has a cash flow conversion efficiency ratio of 0.049x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-178.46K ≈ $-129.09K USD) by net assets (CA$-3.65 Million ≈ $-2.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Marvel Biosciences Corp for the company's overall valuation and market capitalisation.
Marvel Biosciences Corp - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Marvel Biosciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Marvel Biosciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marvel Biosciences Corp ranked by their cash flow conversion efficiency. See Marvel Biosciences Corp (MRVL) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beowulf Mining PLC
ST:BEO-SDB
|
N/A |
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
N/A |
|
Ecoslops SA
PA:ALESA
|
0.259x |
|
Stenocare AS
CO:STENO
|
0.180x |
|
Rossi Residencial S.A
SA:RSID3
|
-0.033x |
|
Academies Australasia Group Ltd
AU:AKG
|
-0.087x |
|
X2M Connect Ltd
AU:X2M
|
-0.024x |
|
Strategic Energy Resources Limited
F:EB8
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Marvel Biosciences Corp (2020–2025)
The table below shows the annual cash flow conversion efficiency of Marvel Biosciences Corp from 2020 to 2025. View Marvel Biosciences Corp (MRVL) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | CA$-4.01 Million ≈ $-2.90 Million |
CA$-1.15 Million ≈ $-832.13K |
0.287x | -31.21% |
| 2024-07-31 | CA$-2.83 Million ≈ $-2.04 Million |
CA$-1.18 Million ≈ $-853.23K |
0.417x | -46.11% |
| 2023-07-31 | CA$-1.72 Million ≈ $-1.24 Million |
CA$-1.33 Million ≈ $-963.72K |
0.775x | +106.90% |
| 2022-07-31 | CA$195.54K ≈ $141.45K |
CA$-2.19 Million ≈ $-1.59 Million |
-11.220x | -1828.46% |
| 2021-07-31 | CA$2.36 Million ≈ $1.70 Million |
CA$-1.37 Million ≈ $-991.45K |
-0.582x | +87.16% |
| 2020-07-31 | CA$118.80K ≈ $85.94K |
CA$-538.53K ≈ $-389.57K |
-4.533x | -- |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more